Wyeth on Thursday showed signs that renewed interest in vaccines is paying off for drugmakers, as booming sales of its Prevnar vaccine helped lift quarterly profits 18 per cent.

The US drugmaker reported strong growth worldwide and suggested a bright future in international markets for Prevnar, a vaccine to prevent pneumonia in children. Prevnar sales jumped 60 per cent to $518m, helped by its introduction into the UK’s immunisation programme.